marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Magenta Therapeutics Balance Sheet 2011-2024 | MGTA
Annual Balance Sheet Magenta Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-132 M | -14.6 M | - | -58.2 M | -65.1 M | -58.3 M | -51.4 M | -4.51 M | - | - | - | - | - |
Long Term Debt |
168 K | 438 K | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
417 K | 350 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 6.28 M | 6.21 M | 1.25 M | - | - | - | - | - | - | - |
Total Current Liabilities |
9.63 M | 8.22 M | 10.9 M | 11.4 M | 14.1 M | 10.4 M | - | - | - | - | - | - | - |
Total Liabilities |
10.5 M | 9.45 M | 17.3 M | 17.7 M | 20.3 M | 11.7 M | 4.14 M | 2.3 M | - | - | - | - | - |
Deferred Revenue |
100 K | 100 K | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-89.4 M | -45.9 M | -326 M | -254 M | -179 M | -103 M | -45.2 M | -9.72 M | - | - | - | - | - |
Total Assets |
179 M | 83.1 M | 190 M | 162 M | 162 M | 157 M | 54.5 M | 11.3 M | - | - | - | - | - |
Cash and Cash Equivalents |
132 M | 15.4 M | 132 M | 58.2 M | 65.1 M | 58.3 M | 51.6 M | 4.54 M | - | - | - | - | - |
Book Value |
169 M | 73.7 M | 173 M | 144 M | 141 M | 146 M | 50.3 M | 9.04 M | - | - | - | - | - |
Total Shareholders Equity |
169 M | -44.4 M | 173 M | 144 M | 141 M | 146 M | -42.1 M | -8.87 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Magenta Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 30 K | 97 K | 168 K | 257 K | - | - | 438 K | 27.2 M | - | 29.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.25 M | 1.08 M | 796 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
16.4 M | 10.7 M | 9.78 M | 10.5 M | 14.1 M | 4.03 M | 5.98 M | 9.45 M | 40.1 M | - | 43.2 M | 17.3 M | 16.5 M | 17.5 M | 15.6 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 4.14 M | 4.14 M | 4.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
100 K | 100 K | 100 K | 100 K | 100 K | - | - | 100 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-146 M | -121 M | -103 M | -89.4 M | -78.9 M | -434 M | -431 M | -45.9 M | -78.9 M | - | -349 M | -326 M | -306 M | -289 M | -272 M | -254 M | -254 M | -254 M | -254 M | -179 M | -179 M | -179 M | -179 M | -103 M | -103 M | -103 M | -103 M | -45.2 M | -45.2 M | -45.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
354 M | 369 M | 382 M | 179 M | 192 M | 78.6 M | 83.4 M | 83.1 M | 164 M | - | 194 M | 190 M | 206 M | 220 M | 145 M | 162 M | 162 M | 162 M | 162 M | 162 M | 162 M | 162 M | 162 M | 157 M | 157 M | 157 M | 157 M | 54.5 M | 54.5 M | 54.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
33.7 M | 314 M | 330 M | 132 M | 157 M | 40.3 M | 23.2 M | 15.4 M | 36.9 M | 56.6 M | 73.5 M | 132 M | 159 M | 155 M | 49.3 M | 58.2 M | 58.2 M | 58.2 M | 58.2 M | 65.1 M | 65.1 M | 65.1 M | 65.1 M | 58.3 M | 58.3 M | 58.3 M | 58.3 M | 51.4 M | 51.4 M | 51.4 M | - | 4.51 M | - | - | - | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
338 M | 358 M | 373 M | 169 M | 178 M | 74.6 M | 77.5 M | 73.7 M | 124 M | - | 151 M | 173 M | 190 M | 203 M | 129 M | 144 M | 144 M | 144 M | 144 M | 141 M | 141 M | 141 M | 141 M | 146 M | 146 M | 146 M | 146 M | 50.3 M | 50.3 M | 50.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
338 M | 358 M | 373 M | 169 M | 178 M | -61.5 M | -50.8 M | -44.4 M | -34.8 M | 136 M | 151 M | 173 M | 190 M | 203 M | 129 M | 144 M | 144 M | 144 M | 144 M | 141 M | 141 M | 141 M | 141 M | 146 M | 146 M | 146 M | 146 M | -42.1 M | -42.1 M | -42.1 M | - | -8.87 M | - | - | - | -289 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency